Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001140361-20-010906
Filing Date
2020-05-07
Accepted
2020-05-07 07:10:32
Documents
70
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10q.htm 10-Q 653600
2 EXHIBIT 10.1 ex10_1.htm EX-10.1 94844
3 EXHIBIT 31.1 ex31_1.htm EX-31.1 10787
4 EXHIBIT 32.1 ex32_1.htm EX-32.1 6578
  Complete submission text file 0001140361-20-010906.txt   4766896

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT rexn-20200331.xml EX-101.INS 1183260
6 XBRL TAXONOMY EXTENSION SCHEMA rexn-20200331.xsd EX-101.SCH 44831
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE rexn-20200331_cal.xml EX-101.CAL 44865
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rexn-20200331_def.xml EX-101.DEF 133478
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE rexn-20200331_lab.xml EX-101.LAB 323210
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rexn-20200331_pre.xml EX-101.PRE 276689
Mailing Address 15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE MD 20850
Business Address 15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE MD 20850 2402685300
REXAHN PHARMACEUTICALS, INC. (Filer) CIK: 0001228627 (see all company filings)

EIN.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34079 | Film No.: 20854541
SIC: 2834 Pharmaceutical Preparations